Eagle Legend Asia Limited provided consolidated earnings guidance for the year ended December 31, 2013. For the year, the group expected to record a profit as compared to a loss for the year ended December 31, 2012. The factors attributable to the profit include the increase in revenue generated from Hong Kong segment; the recognition of gain on disposal of an available-for-sale investment; and the recognition of gain due to the acquisition of Jiangxi Newoman Pharmaceutical Co.

Ltd.